Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain

Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain PR Newswire CAMBRIDGE, England, July 18, 2012 CAMBRIDGE, England, July 18, 2012 /PRNewswire/ -- Phase I study data indicates CNV2197944's optimal profile for a chronic pain medication Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it is designing Phase II proof of concept studies with CNV2197944 in neuropathic pain, following successful completion of Phase I. This novel, small molecule, state-dependent calcium channel blocker, is designed to selectively inhibit highly active Cav2.2 channels. It is the only truly selective Cav2.2 blocker in clinical development and has the potential to be a first in class treatment for chronic pain. Convergence is conducting the development of CNV2197944 on behalf of Calchan Ltd. Results of the Phase I, placebo-controlled, multiple ascending dose clinical study with orally administered CNV2197944, demonstrated that the drug was well tolerated in all subjects, with few adverse events reported at doses that are expected to fall within the predicted therapeutic range. The compound was also well absorbed following oral administration, with a pharmacokinetic profile that is predictable and consistent in both young and elderly subjects.